siRNA-Based Approaches for Castration-Resistant Prostate Cancer Therapy Targeting the Androgen Receptor Signaling Pathway

References

• Wang L , LuB, HeM, WangY, WangZ, DuL. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front. Public Health10, 811044 (2022).
   PubMed Web of Science ®Google Scholar
• Sung H , FerlayJ, SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Culp MB , SoerjomataramI, EfstathiouJA, BrayF, JemalA. Recent global patterns in prostate cancer incidence and mortality rates. Eur. Urol.77(1), 38–52 (2019).
   PubMed Web of Science ®Google Scholar
• Aurilio G , CimadamoreA, MazzucchelliRet al. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells9(2653), 1–14 (2020).
   Google Scholar
• Kamoto T . Evaluation and diagnosis for castration resistant prostate cancer: CRPC. Nihon Rinsho72(12), 2103–2107 (2014).
   PubMedGoogle Scholar
• Scher HI , HalabiS, TannockIet al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol.26(7), 1148–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Morote J , AguilarA, PlanasJ. Definition of castrate resistant prostate cancer: new insights. Biomedicines10, 689 (2022).
   PubMed Web of Science ®Google Scholar
• Shan X , LuD, ChenY. Efficacy and safety of androgen-deprivation therapy combined with docetaxel plus prednisone in high-burden metastatic hormone-sensitive prostate cancer. Cancer Manag. Res.12, 4369–4377 (2020).
   PubMed Web of Science ®Google Scholar
• Pernigoni N , ZagatoE, CalcinottoAet al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. J. Urol.208(1), 205–206 (2022).
   PubMed Web of Science ®Google Scholar
• Kong P , ZhangL, ZhangZet al. Emerging proteins in CRPC: functional roles and clinical implications. Front. Oncol.12, 873876 (2022).
   PubMed Web of Science ®Google Scholar
• Huang J , LinB, LiB, CuvillierO. Anti-androgen receptor therapies in prostate cancer: a brief update and perspective. Front. Oncol.12, 865350 (2022).
   PubMed Web of Science ®Google Scholar
• Lokeshwar SD , KlaassenZ, SaadF. Treatment and trials in non-metastatic castration-resistant prostate cancer. Nat. Rev. Urol.18(7), 433–442 (2021).
   PubMed Web of Science ®Google Scholar
• Kristen AV , Ajroud-DrissS, ConceiçãoI, GorevicP, KyriakidesT, ObiciL. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener. Dis. Manag.9(1), 5–23 (2019).
   PubMed Web of Science ®Google Scholar
• Scott LJ . Givosiran: first approval. Drugs80(3), 335–339 (2020).
   PubMed Web of Science ®Google Scholar
• Scott LJ , KeamSJ. Lumasiran: first approval. Drugs81(2), 277–282 (2021).
   PubMed Web of Science ®Google Scholar
• Padda IS , MahtaniAU, ParmarM. Small Interfering RNA (siRNA) Based Therapy.StatPearls Publishing, Treasure Island (FL) (2023).
   Google Scholar
• Ray KK , WrightRS, KallendDet al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N. Engl. J. Med.382(16), 1507–1519 (2020).
   PubMed Web of Science ®Google Scholar
• Mullard A . 2022 FDA approvals. Nat. Rev. Drug Discov.22(2), 83–88 (2023).
   PubMed Web of Science ®Google Scholar
• Mullard A . FDA approves fifth RNAi drug – Alnylam’s next-gen hATTR treatment. Nat. Rev. Drug Discov.21(8), 548–549 (2022).
   Web of Science ®Google Scholar
• Yamamoto Y , LinPJC, BeraldiEet al. siRNA lipid nanoparticle potently silences clusterin and delays progression when combined with androgen receptor cotargeting in enzalutamide-resistant prostate cancer. Clin. Cancer Res.21(21), 4845–4855 (2015).
   PubMed Web of Science ®Google Scholar
• Albala DM . Imaging and treatment recommendations in patients with castrate-resistant prostate cancer. Rev. Urol.19(3), 200–202 (2017).
   PubMedGoogle Scholar
• Vellky JE , RickeWA. Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia.22(11), 566–575 (2020).
   PubMed Web of Science ®Google Scholar
• Massengill JC , SunL, MoulJWet al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J. Urol.169(5), 1670–1675 (2003).
   PubMed Web of Science ®Google Scholar
• Schatzl G , MadersbacherS, ThurridlTet al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate47(1), 52–58 (2001).
   PubMed Web of Science ®Google Scholar
• Intasqui P , BertollaRP, SadiMV. Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives. Expert Rev. Proteomics15(1), 65–79 (2018).
   PubMed Web of Science ®Google Scholar
• Liu X , PapukashviliD, WangZet al. Potential utility of miRNAs for liquid biopsy in breast cancer. Front. Oncol.12, 940314 (2022).
   PubMed Web of Science ®Google Scholar
• Iglesias-Gato D , WikströmP, TyanovaSet al. The proteome of primary prostate cancer. Eur. Urol.69(5), 942–952 (2016).
   PubMed Web of Science ®Google Scholar
• Trujillo B , WuA, WetterskogD, AttardG. Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. Br. J. Cancer127(8), 1394–1402 (2022).
   PubMed Web of Science ®Google Scholar
• PDQ Adult Treatment Editorial Board . Prostate Cancer Treatment (PDQ^®): Patient Version.National Cancer Institute, Bethesda, MD (2023).
   Google Scholar
• Morgan SC , HoffmanK, LoblawDAet al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO and AUA evidence-based guideline. J. Urol.201(3), 528–534 (2019).
   PubMed Web of Science ®Google Scholar
• Posdzich P , DarrC, HilserTet al. Metastatic prostate cancer – a review of current treatment options and promising new approaches. Cancers (Basel)15(2), 461 (2023).
   PubMed Web of Science ®Google Scholar
• Papukashvili D , RcheulishviliN, LiuCet al. Perspectives on miRNAs targeting DKK1 for developing hair regeneration therapy. Cells10(11), 2957 (2021).
   PubMed Web of Science ®Google Scholar
• Daniels DL , WeisWI. β-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat. Struct. Mol. Biol.12(4), 364–371 (2005).
   PubMed Web of Science ®Google Scholar
• Mehta S , HingoleS, ChaudharyV. The emerging mechanisms of Wnt secretion and signaling in development. Front. Cell Dev. Biol.9, 714746 (2021).
   PubMed Web of Science ®Google Scholar
• Kimelman D , XuW. β-Catenin destruction complex: insights and questions from a structural perspective. Oncogene25(57), 7482–7491 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang Y , WangX. Targeting the Wnt/β-catenin signaling pathway in cancer. J. Hematol. Oncol.13, 165 (2020).
   PubMed Web of Science ®Google Scholar
• Kypta RM , WaxmanJ. Wnt/β 2-catenin signalling in prostate cancer. Nat. Rev. Urol.9(8), 418–428 (2012).
   PubMed Web of Science ®Google Scholar
• Murillo-Garzón V , KyptaR. Wnt signalling in prostate cancer. Nat. Rev. Urol.14(11), 683–69 (2017).
   PubMed Web of Science ®Google Scholar
• Domingo-Domenech J , MelladoB, FerrerBet al. Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse. Br. J. Cancer93(11), 1285–1294 (2005).
   PubMed Web of Science ®Google Scholar
• Staal J , BeyaertR. Inflammation and NF-κB signaling in prostate cancer: mechanisms and clinical implications. Cells7(9), 122 (2018).
   PubMed Web of Science ®Google Scholar
• Jin R , YamashitaH, YuXet al. Inhibition of NF-kappa B signaling restores responsiveness of castrate resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor variants expression. Oncogene34(28), 3700–3710 (2015).
   PubMed Web of Science ®Google Scholar
• He Y , XuW, XiaoYT, HuangH, GuD, RenS. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct. Target. Ther.7(1), 198 (2022).
   PubMed Web of Science ®Google Scholar
• Hoang DT , IczkowskiKA, KilariD, SeeW, NevalainenMT. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: opportunities for therapeutic targeting from multiple angles. Oncotarget8(2), 3724–3745 (2017).
   PubMedGoogle Scholar
• Ramalingam S , RamamurthyVP, NjarVCO. Dissecting major signaling pathways in prostate cancer development and progression: mechanisms and novel therapeutic targets. J. Steroid Biochem. Mol. Biol.166, 16–27 (2017).
   PubMed Web of Science ®Google Scholar
• Shorning BY , DassMS, SmalleyMJ, PearsonHB. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int. J. Mol. Sci.21(12), 4507 (2020).
   PubMed Web of Science ®Google Scholar
• Molina JR , AdjeiAA. The Ras/Raf/MAPK pathway. J. Thorac. Oncol.1(1), 7–9 (2006).
   PubMed Web of Science ®Google Scholar
• Schweizer MT , YuEY. Persistent androgen receptor addiction in castration-resistant prostate cancer. J. Hematol. Oncol.8(1), 128 (2015).
   PubMedGoogle Scholar
• El-amm J , Aragon-chingJB. The current landscape of treatment in non-metastatic castration-resistant prostate cancer. Clin. Med. Insights Oncol.13, 1179554919833927 (2019).
   Web of Science ®Google Scholar
• Hamid ARAH , Luna-VelezMV, DudekAM, SchaafsmaE, SedelaarJPM, SchalkenJA. Molecular phenotyping of AR signaling for predicting targeted therapy in castration resistant prostate cancer patient and tissue selection. Front. Oncol.11, 721659 (2021).
   PubMed Web of Science ®Google Scholar
• Chang C , LeeSO, WangRS, YehS, ChangTM. Androgen receptor (AR) physiological roles in male and female reproductive systems: lessons learned from AR-knockout mice lacking AR in selective cells. Biol. Reprod.89(1), 21 (2013).
   PubMed Web of Science ®Google Scholar
• Fujita K , NonomuraN. Role of androgen receptor in prostate cancer: a review. World J. Mens Health.37(3), 288–295 (2019).
   PubMedGoogle Scholar
• Eder IE , CuligZ, PutzT, Nessler-MenardiC, BartschG, KlockerH. Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur. Urol.40(3), 241–251 (2001).
   PubMed Web of Science ®Google Scholar
• Tan ME , LiJ, XuHE, MelcherK, YongEL. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol. Sin.36(1), 3–23 (2015).
   PubMed Web of Science ®Google Scholar
• Schalken J , FitzpatrickJM. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int.117(2), 215–225 (2016).
   PubMed Web of Science ®Google Scholar
• Robinson JLL , HickeyTE, WarrenAYet al. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. Oncogene33(50), 5666–5674 (2014).
   PubMed Web of Science ®Google Scholar
• Coutinho I , DayTK, TilleyWD, SelthLA. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr. Relat. Cancer.23(12), T179–T197 (2016).
   PubMed Web of Science ®Google Scholar
• Grasso CS , WuY, RobinsonDRet al. The mutational landscape of lethal castrate resistant prostate cancer. Nature487(7406), 239–243 (2013).
   Web of Science ®Google Scholar
• Podolak J , EilersK, NewbyTet al. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget8(42), 71447–71455 (2017).
   PubMedGoogle Scholar
• Azad AA , VolikSV, WyattAWet al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer Res.21(10), 2315–2324 (2015).
   PubMed Web of Science ®Google Scholar
• Jiang Y , PalmaJF, AgusDB, WangY, GrossME. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin. Chem.56(9), 1492–1495 (2010).
   PubMed Web of Science ®Google Scholar
• Kwack MH , SungYK, ChungEJet al. Dihydrotestosterone-inducible dickkopf 1 from balding dermal papilla cells causes apoptosis in follicular keratinocytes. J. Invest. Dermatol.128(2), 262–269 (2008).
   PubMed Web of Science ®Google Scholar
• Premanand A , RajkumariBR. Androgen modulation of Wnt/β-catenin signaling in androgenetic alopecia. Arch. Dermatol. Res.310, 391–399 (2018).
   PubMed Web of Science ®Google Scholar
• Yassa M , SaliouM, derycke Yet al. Male pattern baldness and the risk of prostate cancer. Ann. Oncol.22(8), 1824–1827 (2011).
   PubMed Web of Science ®Google Scholar
• Muller DC , GilesGG, SinclairR, HopperJL, EnglishDR, SeveriG. Age-dependent associations between androgenetic alopecia and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev.22(2), 209–215 (2013).
   PubMed Web of Science ®Google Scholar
• He H , XieB, XieL. Male pattern baldness and incidence of prostate cancer: a systematic review and meta-analysis. Medicine97(28), e11379 (2017).
   Web of Science ®Google Scholar
• Wright JL , PageST, LinDW, StanfordJL. Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiol.34(2), 131–135 (2010).
   PubMed Web of Science ®Google Scholar
• Khan S , CaldwellJ, WilsonKM, Gonzalez-felicianoAG, GerkeTA, MarktSC. Baldness and risk of prostate cancer in the Health Professionals Follow-Up Study. Cancer Epidemiol. Biomarkers Prev.29(6), 1229–1236 (2020).
   PubMedGoogle Scholar
• Flores-Morales A , BergmannTB, LavalleeCet al. Proteogenomic characterization of patient-derived xenografts highlights the role of REST in neuroendocrine differentiation of castration-resistant prostate cancer. Clin. Cancer Res.15(2), 595–608 (2019).
   Google Scholar
• Parsons JK , CarterHB, PlatzEA, WrightEJ, LandisP, MetterEJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol. Biomarkers Prev.14(9), 2257–2260 (2005).
   PubMed Web of Science ®Google Scholar
• Pierorazio PM , FerrucciL, KettermannA, LongoDL, MetterEJ, CarterHB. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int.105(6), 824–829 (2010).
   PubMedGoogle Scholar
• Stattin P , LummeS, TenkanenLet al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int. J. Cancer108(3), 418–424 (2004).
   PubMed Web of Science ®Google Scholar
• Gui B , GuiF, TakaiTet al. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proc. Natl Acad. Sci. USA116(29), 14573–14582 (2019).
   PubMed Web of Science ®Google Scholar
• Tatarov O , MitchellTJ, SeywrightM, LeungHY, BruntonVG, EdwardsJ. Src family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin. Cancer Res.15(10), 3540–3549 (2009).
   PubMed Web of Science ®Google Scholar
• Peacock JW , TakeuchiA, HayashiNet al. SEMA 3C drives cancer growth by transactivating multiple receptor tyrosine kinases via plexin B1. EMBO Mol. Med.10(2), 219–238 (2018).
   PubMed Web of Science ®Google Scholar
• Lee CCW , MunugantiRSN, PeacockJWet al. Targeting semaphorin 3C in prostate cancer with small molecules. J. Endocr. Soc.2(12), 1381–1394 (2018).
   PubMedGoogle Scholar
• Xu K , ShimelisH, LinnDEet al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell15(4), 270–282 (2009).
   PubMed Web of Science ®Google Scholar
• Welti J , RodriguesDN, SharpAet al. Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer. Eur. Urol.70(4), 599–608 (2016).
   PubMed Web of Science ®Google Scholar
• Sugiura M , SatoH, OkabeAet al. Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer. Transl. Oncol.14(1), 100915 (2021).
   PubMed Web of Science ®Google Scholar
• Xu D , ZhanY, QiYet al. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res.75(17), 3663–3671 (2015).
   PubMed Web of Science ®Google Scholar
• Stuopelyte K , SabaliauskaiteR, BakaviciusAet al. Analysis of AR-FL and AR-V1 in whole blood of patients with castration resistant prostate cancer as a tool for predicting response to abiraterone acetate. J. Urol.204(1), 71–78 (2020).
   PubMed Web of Science ®Google Scholar
• Li Q , WangZ, YiJet al. Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: a systematic review and meta-analysis. Transl. Oncol.14(9), 101145 (2021).
   PubMed Web of Science ®Google Scholar
• Sharp A , ColemanI, YuanWet al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J. Clin. Invest.129(1), 192–208 (2019).
   PubMed Web of Science ®Google Scholar
• Kanayama M , LuC, LuoJ, AntonarakisES. AR splicing variants and resistance to AR targeting agents. Cancers (Basel)13(11), 2563 (2021).
   PubMed Web of Science ®Google Scholar
• Heinlein CA , ChangC. Androgen receptor (AR) coregulators: an overview. Endocr. Rev.23(2), 175–200 (2002).
   PubMed Web of Science ®Google Scholar
• Watson PA , AroraVK, SawyersCL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer15(12), 701–711 (2015).
   PubMed Web of Science ®Google Scholar
• Hu R , DunnTA, WeiSet al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone refractory prostate cancer. Cancer Res.69(1), 16–22 (2009).
   PubMed Web of Science ®Google Scholar
• Jiang N , Hjorth-JensenK, HekmatOet al. In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth. Oncogene34(21), 2764–2776 (2015).
   PubMed Web of Science ®Google Scholar
• Lee HC , OuCH, HuangYCet al. YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. Oncogene40(13), 2407–2421 (2021).
   PubMed Web of Science ®Google Scholar
• Ishizuya Y , UemuraM, NarumiRet al. The role of actinin-4 (ACTN4) in exosomes as a potential novel therapeutic target in castration-resistant prostate cancer. Biochem. Biophys. Res. Commun.523(3), 588–594 (2020).
   PubMed Web of Science ®Google Scholar
• Park S , KangM, KimS, AnH, GettemansJ, KoJ. α-Actinin-4 promotes the progression of prostate cancer through the Akt/GSK-3β/β-catenin signaling pathway. Front. Cell Dev. Biol.8, 588544 (2020).
   PubMed Web of Science ®Google Scholar
• Ingersoll MA , ChouYW, LinJSet al. p66Shc regulates migration of castration-resistant prostate cancer cells. Cell. Signal.46, 1–14 (2018).
   PubMed Web of Science ®Google Scholar
• Miller DR , IngersollMA, ChatterjeeAet al. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance. Free Radic. Biol. Med.139, 24–34 (2019).
   PubMed Web of Science ®Google Scholar
• Ai J , JinT, YangLet al. Vinculin and filamin-C are two potential prognostic biomarkers and therapeutic targets for prostate cancer cell migration. Oncotarget8(47), 82430–82436 (2017).
   PubMedGoogle Scholar
• Ai J , LuY, WeiQ, LiH. Comparative proteomics uncovers correlated signaling network and potential biomarkers for progression of prostate cancer. Cell. Physiol. Biochem.41(1), 1–9 (2017).
   PubMedGoogle Scholar
• Bahmad HF , PengW, ZhuRet al. Protein expression analysis of an in vitro murine model of prostate cancer progression: towards identification of high-potential therapeutic targets. J. Pers. Med.10(3), 83 (2020).
   PubMed Web of Science ®Google Scholar
• Ni J , CozziP, HaoJet al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int. J. Biochem. Cell Biol.45(12), 2736–2748 (2013).
   PubMed Web of Science ®Google Scholar
• Saraon P , CretuD, MusrapNet al. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Mol. Cell. Proteomics12(6), 1589–1601 (2013).
   PubMed Web of Science ®Google Scholar
• Labanca E , BizzottoJ, SanchisPet al. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene40, 6284–6298 (2021).
   PubMed Web of Science ®Google Scholar
• Höti N , YangS, HuY, ShahP, HaffnerMC, ZhangH. Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells. Prostate Cancer Prostatic Dis.21(1), 137–146 (2018).
   PubMed Web of Science ®Google Scholar
• Wang X , ChenJ, LiQKet al. Overexpression of α(1,6) fucosyltransferase associated with aggressive prostate cancer. Glycobiology24(10), 935–944 (2014).
   PubMed Web of Science ®Google Scholar
• Höti N , ShahP, HuY, YangS, ZhangH. Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance. Proteomics.17(6), 10.1002/pmic.201600228 (2017).
   PubMed Web of Science ®Google Scholar
• Ferrari N , GranataI, CapaiaMet al. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer. Cell Commun. Signal.15(1), 51 (2017).
   PubMedGoogle Scholar
• Barboro P , BenelliR, TosettiFet al. Aspartate β-hydroxylase targeting in castration-resistant prostate cancer modulates the NOTCH/HIF1α/GSK3β crosstalk. Carcinogenesis41(9), 1246–1252 (2020).
   PubMed Web of Science ®Google Scholar
• Blomme A , FordCA, MuiEet al. 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nat. Commun.11(1), 2508 (2020).
   PubMed Web of Science ®Google Scholar
• Gong Y , Chippada-venkataUD, GalskyMD, HuangJ, OhWK. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. Prostate75(6), 616–627 (2015).
   PubMed Web of Science ®Google Scholar
• Wise GJ , MarellaVK, TalluriG, ShirazianD. Cytokine variations in patients with hormone treated prostate cancer. J. Urol.164(3 I), 722–725 (2000).
   PubMed Web of Science ®Google Scholar
• Izumi K , FangLY, MizokamiAet al. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol. Med.5(9), 1383–1401 (2013).
   PubMed Web of Science ®Google Scholar
• Papukashvili D , LiuC, RcheulishviliNet al. DKK1-targeting cholesterol-modified siRNA implication in hair growth regulation. Biochem. Biophys. Res. Commun.668, 55–61 (2023).
   PubMed Web of Science ®Google Scholar
• Zhao J , LinH, WangL, GuoK, JingR, LiX. Suppression of FGF5 and FGF18 expression by cholesterol-modified siRNAs promotes hair growth in mice. Front. Pharmacol.12, 666860 (2021).
   PubMed Web of Science ®Google Scholar
• Alshaer W , ZureigatH, AlAet al. siRNA: mechanism of action, challenges, and therapeutic approaches. Eur. J. Pharmacol.905, 174178 (2021).
   PubMed Web of Science ®Google Scholar
• Subhan MA , AttiaSA, TorchilinVP. Advances in siRNA delivery strategies for the treatment of MDR cancer. Life Sci.274, 119337 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang MM , BahalR, RasmussenTP, ManautouJE, ZhongX-B. The growth of siRNA-based therapeutics: updated clinical studies. Biochem. Pharmacol.189, 114432 (2021).
   PubMed Web of Science ®Google Scholar
• Lam JKW , ChowMYT, ZhangY, LeungSWS. siRNA versus miRNA as therapeutics for gene silencing. Mol. Ther. Nucleic Acids4(9), e252 (2015).
   PubMedGoogle Scholar
• Ahn I , KangC, HanJ. Where should siRNAs go: applicable organs for siRNA drugs. Exp. Mol. Med.55(7), 1283–1292 (2023).
   PubMed Web of Science ®Google Scholar
• Jing X , AryaV, ReynoldsKS, RogersH. Clinical pharmacology of RNA interference–based therapeutics: a summary based on Food and Drug Administration-approved small interfering RNAs. Drug Metab. Dispos.51(2), 193–198 (2023).
   PubMed Web of Science ®Google Scholar
• Hariharan VN , ShinM, ChangC-Wet al. Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection. Proc. Natl Acad. Sci. USA120(11), 2017 (2017).
   Google Scholar
• Kim H , MunD, KangJY, LeeSH, YunN, JoungB. Improved cardiac-specific delivery of RAGE siRNA within small extracellular vesicles engineered to express intense cardiac targeting peptide attenuates myocarditis. Mol. Ther. Nucleic Acids24, 1024–1032 (2021).
   PubMedGoogle Scholar
• Tang W , ChenY, JangHSet al. Preferential siRNA delivery to injured kidneys for combination treatment of acute kidney injury. J. Control. Release341, 300–313 (2022).
   PubMed Web of Science ®Google Scholar
• Khan T , WeberH, DimuzioJet al. Silencing myostatin using cholesterol-conjugated siRNAs induces muscle growth. Mol. Ther. Nucleic Acids5(8), e342 (2016).
   PubMedGoogle Scholar
• Yan H , HuY, AkkA, WicklineSA, PanH, PhamCTN. Peptide-siRNA nanoparticles targeting NF-κB p50 mitigate experimental abdominal aortic aneurysm progression and rupture. Biomater. Adv.139, 213009 (2022).
   PubMedGoogle Scholar
• Nanna AR , Kel'inAV, TheileCet al. Generation and validation of structurally defined antibody–siRNA conjugates. Nucleic Acids Res.48(10), 5281–5293 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang Y , DuanH, ZhaoHet al. Development and evaluation of a PSMA-targeted nanosystem co-packaging docetaxel and androgen receptor siRNA for castration-resistant prostate cancer treatment. Pharmaceutics14(5), 964 (2022).
   PubMed Web of Science ®Google Scholar
• Diao Y , WangG, ZhuBet al. Loading of ‘cocktail siRNAs’ into extracellular vesicles via TAT-DRBD peptide for the treatment of castration-resistant prostate cancer. Cancer Biol. Ther.23(1), 163–172 (2022).
   PubMed Web of Science ®Google Scholar
• Chen J , YangY, XuDet al. Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo. Biochem. Biophys. Res. Commun.540, 83–89 (2021).
   PubMed Web of Science ®Google Scholar
• Compagno D , MerleC, MorinAet al. siRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLOS ONE2(10), e1006 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang X , HeZ, XiangLet al. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer. Drug Des. Devel. Ther.13, 1357–1372 (2019).
   PubMed Web of Science ®Google Scholar
• Oner E , KotmakciM, BairdAMet al. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. J. Nanobiotechnology19, 71 (2021).
   PubMed Web of Science ®Google Scholar
• Liao X , TangS, ThrasherJB, GrieblingTL, LiB. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol. Cancer Ther.4(4), 505–515 (2005).
   PubMed Web of Science ®Google Scholar
• Yang C , MaD, LuL, YangX, XiZ. Synthesis of KUE-siRNA conjugates for prostate cancer cell-targeted gene silencing. ChemBioChem22(19), 2888–2895 (2021).
   PubMed Web of Science ®Google Scholar
• Lee JB , ZhangK, TamYYCet al. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int. J. Cancer131(5), E781–790 (2012).
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M , HushmandiK, MoghadamERet al. Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer. Bioengineering7(3), 91 (2020).
   PubMedGoogle Scholar
• Hattab D , GazzaliAM, BakhtiarA. Clinical advances of siRNA-based nanotherapeutics for cancer treatment. Pharmaceutics13(7), 1009 (2021).
   PubMed Web of Science ®Google Scholar
• Cheng H , SnoekR, GhaidiF, CoxME, RenniePS. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res.66(21), 10613–10620 (2006).
   PubMed Web of Science ®Google Scholar
• Luna Velez MV , VerhaeghGW, SmitF, SedelaarJPM, SchalkenJA. Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis. Oncogene38(19), 3696–3709 (2019).
   PubMed Web of Science ®Google Scholar
• Yang J , XieSX, HuangYet al. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine7(9), 1297–1309 (2012).
   PubMed Web of Science ®Google Scholar
• Corbin JM , GeorgescuC, WrenJD, XuC, AschAS, Ruiz-EchevarríaMJ. Seed-mediated RNA interference of androgen signaling and survival networks induces cell death in prostate cancer cells. Mol. Ther. Nucleic Acids24, 337–351 (2021).
   PubMedGoogle Scholar
• Hååg P , BekticJ, BartschG, KlockerH, EderIE. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J. Steroid Biochem. Mol. Biol.96(3–4), 251–258 (2005).
   PubMed Web of Science ®Google Scholar
• Sun A , TangJ, TerranovaPF, ZhangX, ThrasherJB, LiB. Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical study. Int. J. Cancer126(3), 764–774 (2010).
   PubMed Web of Science ®Google Scholar
• Snoek R , ChengH, MargiottiKet al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin. Cancer Res.15(1), 39–47 (2009).
   PubMed Web of Science ®Google Scholar
• Walsh EE , FrenckRW, FalseyARet al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med.383(25), 2439–2450 (2020).
   PubMed Web of Science ®Google Scholar
• Haas EJ , AnguloFJ, McLaughlinJMet al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet397(10287), 1819–1829 (2021).
   PubMed Web of Science ®Google Scholar
• Corbett KS , FlynnB, FouldsKEet al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med.383(16), 1544–1555 (2020).
   PubMed Web of Science ®Google Scholar
• Wang X , LiuC, RcheulishviliNet al. Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa. NPJ Vaccines8(1), 76 (2023).
   PubMed Web of Science ®Google Scholar
• Liu C , RcheulishviliN, ShenZet al. Development of an LNP-encapsulated mRNA-RBD vaccine against SARS-CoV-2 and its variants. Pharmaceutics14(5), 1101 (2022).
   PubMed Web of Science ®Google Scholar
• Papukashvili D , RcheulishviliN, LiuC, JiY, HeY, WangPG. Self-amplifying RNA approach for protein replacement therapy. Int. J. Mol. Sci.23(21), 12884 (2022).
   PubMed Web of Science ®Google Scholar
• Liu C , PapukashviliD, DongYet al. Identification of tumor antigens and design of mRNA vaccine for colorectal cancer based on the immune subtype. Front. Cell Dev. Biol.9, 783527 (2022).
   PubMed Web of Science ®Google Scholar
• Chaudhary N , WeissmanD, WhiteheadKA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov.20(11), 817–838 (2021).
   PubMed Web of Science ®Google Scholar
• Lu ZJ , MathewsDH. OligoWalk: an online siRNA design tool utilizing hybridization thermodynamics. Nucleic Acids Res.36(Web Server issue), 104–108 (2008).
   Google Scholar
• Mahmoodi Chalbatani G , DanaH, GharagouzlooEet al. Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach. Int. J. Nanomedicine14, 3111–3128 (2019).
   PubMed Web of Science ®Google Scholar
• Wadosky KM , KoochekpourS. Androgen receptor splice variants and prostate cancer: from bench to bedside. Oncotarget8(11), 18550–18576 (2017).
   PubMedGoogle Scholar
• Zheng Z , LiJ, LiuYet al. The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer. Cancers (Basel)14(19), 4877 (2022).
   PubMed Web of Science ®Google Scholar
• Zhao S , LiaoJ, ZhangS, ShenM, LiX, ZhouL. The positive relationship between androgen receptor splice variant-7 expression and the risk of castration-resistant prostate cancer: a cumulative analysis. Front. Oncol.13, 1053111 (2023).
   PubMed Web of Science ®Google Scholar
• Sobhani N , NeeliPK, D'AngeloAet al. AR-V7 in metastatic prostate cancer: a strategy beyond redemption. Int. J. Mol. Sci.22, 5515 (2021).
   PubMed Web of Science ®Google Scholar
• Liu X , LedetE, LiDet al. A whole blood assay for AR-V7 and ARv567es in patients with prostate cancer. J. Urol.196(6), 1758–1763 (2016).
   PubMed Web of Science ®Google Scholar
• Bernemann C , HumbergV, ThielenBet al. Comparative analysis of AR variant AR-V567es mRNA detection systems reveals eminent variability and questions the role as a clinical biomarker in prostate cancer. Clin. Cancer Res.25(13), 3856–3864 (2019).
   PubMed Web of Science ®Google Scholar
• Kohli M , HoY, HillmanDWet al. Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance. Clin. Cancer Res.23(16), 4704–4715 (2017).
   PubMed Web of Science ®Google Scholar
• Kallio HML , HietaR, LatonenLet al. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. Br. J. Cancer119(3), 347–356 (2018).
   PubMed Web of Science ®Google Scholar
• Ledford H . Gene-silencing drug approved. Nature560(7718), 291–292 (2018).
   PubMed Web of Science ®Google Scholar
• Hoy SM . Patisiran: first global approval. Drugs78(15), 1625–1631 (2018).
   PubMed Web of Science ®Google Scholar
• Mullard A . RNAi agents score an approval and drive an acquisition. Nat. Rev. Drug Discov.19(1), 10 (2020).
   Web of Science ®Google Scholar
• Mullard A . 2020 FDA drug approvals. Nat. Rev. Drug Discov.20(2), 85–90 (2021).
   PubMed Web of Science ®Google Scholar
• Mullard A . 2021 FDA approvals. Nat. Rev. Drug Discov.21(2), 83–88 (2022).
   PubMed Web of Science ®Google Scholar